Piper Sandler Downgrades Eagle Pharmaceuticals to Underweight, Lowers Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst David Amsellem has downgraded Eagle Pharmaceuticals (NASDAQ:EGRX) from Neutral to Underweight and lowered the price target from $26 to $17.
August 09, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eagle Pharmaceuticals has been downgraded by Piper Sandler from Neutral to Underweight, with a reduced price target from $26 to $17.
The downgrade from Piper Sandler is a negative signal for Eagle Pharmaceuticals. The reduction in price target from $26 to $17 suggests that the analyst sees less upside potential in the stock, which could lead to selling pressure and a potential decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100